SCHEMBL23950286

SCHEMBL23950286

CCC(CO)n1cnc2c(-c3cccc(F)c3)nc(-c3ccc(Cl)cc3)cc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.41
CNR1 P21554 1/20 0.40
ADORA1 P30542 3/20 0.39
AKR1B10 O60218 2/20 0.36
PDE4A P27815 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
PDE4B Q07343 1/20 0.35
TGFBR1 P36897 4/20 0.34
MALT1 Q9UDY8 1/20 0.34
PSD A5PKW4 2/20 0.34
KDM5B Q9UGL1 1/20 0.33
TGFBR2 P37173 1/20 0.33
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23390464 0.89 AHR (0.42) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL29611147 0.89 AHR (0.42) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL23390466 0.89 AHR (0.42) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL23390386 0.88 AHR (0.41) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL29611427 0.88 AHR (0.41) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL23390388 0.88 AHR (0.41) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL23950588 0.86 PSD (0.41) CNR1ADORA1PDE4APDE4CPDE4D
SCHEMBL23390090 0.83 CYP1A2 (0.37) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL23390088 0.83 CYP1A2 (0.37) AHRCNR1ADORA1AKR1B10PDE4A
SCHEMBL29611413 0.83 CYP1A2 (0.37) AHRCNR1ADORA1AKR1B10PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 AHR 1/4885CNR1 175/4885ADORA1 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.